Your browser doesn't support javascript.
mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
Wang, Haomeng; Chen, Zhao; Wang, Zhenghua; Li, Jin; Yan, Zhihong; Yuan, Jinbo; Zhu, Airu; Chen, Lan; Liu, Ye; Hu, Chenlong; Zhu, Ali; Li, Guowei; Li, Yuehu; Deng, Jie; Ma, Liqiao; Sui, Xiuwen; Miao, Wei; Li, Junqiang; Zheng, Xiuyu; Piao, Jinhua; Yao, Yanfeng; Rao, Juhong; Shan, Chao; Yuan, Zhiming; Zhao, Jincun; Zhu, Tao.
  • Wang H; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Chen Z; CanSino Biologics, Tianjin, People's Republic of China.
  • Wang Z; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Li J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Yan Z; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Yuan J; CanSino Biologics, Tianjin, People's Republic of China.
  • Zhu A; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Chen L; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Liu Y; CanSino Biologics, Tianjin, People's Republic of China.
  • Hu C; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Zhu A; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Li G; CanSino Biologics, Tianjin, People's Republic of China.
  • Li Y; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Deng J; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Ma L; CanSino Biologics, Tianjin, People's Republic of China.
  • Sui X; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Miao W; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Li J; State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
  • Zheng X; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Piao J; CanSino Biologics, Tianjin, People's Republic of China.
  • Yao Y; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Rao J; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Shan C; CanSino Biologics, Tianjin, People's Republic of China.
  • Yuan Z; CanSino (Shanghai) Biological Research Co., Ltd, Shanghai, People's Republic of China.
  • Zhao J; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
  • Zhu T; CanSino (Shanghai) Biotechnologies Co., Ltd, Shanghai, People's Republic of China.
Emerg Microbes Infect ; 11(1): 1550-1553, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1860765
ABSTRACT
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article